AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01041027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01041027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01041027 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo HDR brachytherapy
Study NCT01041027 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT01041027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01004822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study NCT01004822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study NCT01004822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study NCT01004822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study NCT01004822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study NCT01004822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study NCT01004822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study NCT01004822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study NCT02410057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-reduced α-lactalbumin formula
Description: Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula
Study NCT02410057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-reduced whey formula
Description: Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
Study NCT02410057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Standard infant formula
Study NCT03878108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LCHF diet
Description: low-carbohydrate, high-fat (LCHF)diet
Study NCT03878108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LFHC diet
Description: low-fat, high-carbohydrate (LFHC) diet
Study NCT00354991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium (+) hydrochlorothiazide
Description: Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
Study NCT03126175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below elbow immobilization
Description: 20cm wide gypsum in the forearm cut to fit the thumb.
Study NCT03126175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Above elbow immobilization
Description: 20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
Study NCT02071823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
Study NCT02400697 — intervention group
Intervention type: OTHER
Intervention: <30 wks gestation or 1500 grams
Description: Outcomes of preterm infants recorded
Study NCT00509275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0027
Description: capsule
Study NCT00509275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03202329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Description: cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
Study NCT03202329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nurse-based care
Description: board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
Study NCT03115723 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Study NCT03115723 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary angiography
Study NCT02909127 — intervention group
Intervention type: OTHER
Intervention: SWALLOWING EVALUATION
Description: Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
Study NCT02909127 — intervention group
Intervention type: OTHER
Intervention: The Functional Independence Measure
Description: The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
Study NCT02909127 — intervention group
Intervention type: OTHER
Intervention: The PEDI-EAT-10
Description: The PEDI-EAT-10 will also be administered.
Study NCT01692990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
Study NCT01692990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil
Description: For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
Study NCT02513732 — intervention group
Intervention type: DEVICE
Intervention: XIENCE Xpedition 2.25 mm stent
Description: Patients receiving XIENCE Xpedition 2.25 mm stent
Study NCT00860756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation CD
Description: A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
Study NCT00993941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous BMSCs transplantation
Description: 10 ml autologous BMSCs(7\~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
Study NCT00993941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conserved therapy
Description: Oral or intravenous administration
Study NCT01477541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PM/ON integration
Description: Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
Study NCT02390869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2-MANT
Description: A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
Study NCT02390869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-MANT
Description: A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
Study NCT04672434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized anti-PD-1 antibody.
Study NCT04672434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.
Study NCT04801992 — intervention group
Intervention type: DEVICE
Intervention: MINI WELL Ready (SIFI SpA, Italy)
Description: Implantation during cataract surgery of the progressive extended depth of focus intraocular lens for the posterior chamber to replace the crystalline lens in the correction of aphakia in adult patients.
Study NCT03640078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acquisition imaging
Description: The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis
Study NCT02776917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab + Paclitaxel
Description: Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
Study NCT02960022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Subjects will receive enzalutamide orally once daily at the same time each day.
Study NCT02960022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
Study NCT02960022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
Study NCT03960788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetate Sodium
Description: Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
Study NCT02528331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Study NCT00942188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189102
Description: Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
Study NCT00942188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received 2 SC injections weekly for 12 weeks.
Study NCT02528331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Study NCT02058940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
Study NCT02515890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Selected subjects received this drug during a portion of the study
Study NCT02515890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Selected subjects received this drug during a portion of the study
Study NCT03603275 — intervention group
Intervention type: DRUG
Intervention: New FVIII products
Description: Kovaltry or Jivi prescribed by the treating Physician
Study NCT00857909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: 1 tablet twice a day
Study NCT00857909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 1 tablet twice a day
Study NCT00857909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04198194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Predictors of events
Description: Apple Heart \& Movement Study in Apple Research app
Study NCT03474666 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strict Glycemic Control Group
Description: The strict protocol adopted to conduct the study was proposed by Keegan e Cols.(2010) to be used among adult LT recipients that consist of a continuous intravenous insulin infusion. The targeted blood glucose range is 80-130 mg/dL. The procedure must be stopped when the patient can ingest at least 50% of liquid diet or receive bolus tube feedings.
Study NCT03474666 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Glycemic Control Group
Description: The targeted blood glucose range is 130-180 mg/dL~* Blood glucose reading: ≤ 180 mg/dL - subcutaneous insulin dose: 0~* Blood glucose reading: ≥181 mg/dL and ≤250 mg/dL - subcutaneous insulin dose: 5 IU~* Blood glucose reading: ≥251 mg/dL and ≤300 mg/dL - subcutaneous insulin dose: 10 IU~* Blood glucose reading: ≥301 - subcutaneous insulin dose: 15 IU
Study NCT00857909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and spironolactone
Description: 5mg twice daily
Study NCT00857909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 25mg twice daily
Study NCT02515890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
Study NCT02515890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Selected subjects received this drug during a portion of the study
Study NCT04519827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Rice-based hydrolysate
Description: A rice-based hydrolysed infant formula with new ingredient
Study NCT02395406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation with Totaltrack
Study NCT02395406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation with Airtraq
Study NCT04519827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Amino Acid-based infant formula
Description: An amino acid-based infant formula
Study NCT02345902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: haloperidol 1.25 mg P.O q.d
Study NCT02345902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo 1.25 mg P.O q.d
Study NCT04650763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.
Study NCT04650763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated blood cell separator to extract PRP
Description: Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.
Study NCT03455751 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGx-guided post-operative pain management
Description: Post-operative pain management as indicated by pharmacogenomic testing results.
Study NCT02249429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimiralisib
Description: 60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
Study NCT02759406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary stent
Study NCT00702871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
Study NCT02345902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-pharmacologic measures
Description: A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
Study NCT02345902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-pharmacologic measures
Description: A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
Study NCT04231903 — intervention group
Intervention type: DEVICE
Intervention: Aortic clamp
Description: In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
Study NCT00702871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucralfate
Description: In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
Study NCT00513292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00513292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00513292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin Hydrochloride
Description: Given IV
Study NCT00513292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin Hydrochloride
Description: Given IV
Study NCT00513292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00513292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00513292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT00513292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00513292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT00513292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT00513292 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV
Study NCT00513292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT00986661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PV-10 (10% rose bengal disodium)
Description: Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
Study NCT04641234 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: As prescribed by the treating physician
Study NCT00663923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photorefractive keratectomy (PRK)
Description: comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
Study NCT00663923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photorefractive keratectomy (PRK)
Description: comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
Study NCT04344236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline oral/nasal rinse
Description: 5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.